150 related articles for article (PubMed ID: 9373240)
1. In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation.
Dorfman DM; Schultze JL; Shahsafaei A; Michalak S; Gribben JG; Freeman GJ; Pinkus GS; Nadler LM
Blood; 1997 Dec; 90(11):4297-306. PubMed ID: 9373240
[TBL] [Abstract][Full Text] [Related]
2. Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells.
Romano C; De Fanis U; Sellitto A; Dalla Mora L; Chiurazzi F; Giunta R; Rotoli B; Lucivero G
Leuk Lymphoma; 2003 Nov; 44(11):1963-71. PubMed ID: 14738151
[TBL] [Abstract][Full Text] [Related]
3. B7 costimulatory molecules from malignant cells in patients with b-cell chronic lymphoproliferative disorders trigger t-cell proliferation.
Trentin L; Perin A; Siviero M; Piazza F; Facco M; Gurrieri C; Galvan S; Adami F; Agostini C; Pizzolo G; Zambello R; Semenzato G
Cancer; 2000 Sep; 89(6):1259-68. PubMed ID: 11002221
[TBL] [Abstract][Full Text] [Related]
4. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition.
Costello RT; Mallet F; Sainty D; Maraninchi D; Gastaut JA; Olive D
Eur J Immunol; 1998 Jan; 28(1):90-103. PubMed ID: 9485189
[TBL] [Abstract][Full Text] [Related]
5. Blocking CD40 - CD154 and CD80/CD86 - CD28 interactions during primary allogeneic stimulation results in T cell anergy and high IL-10 production.
Van Gool SW; Vermeiren J; Rafiq K; Lorr K; de Boer M; Ceuppens JL
Eur J Immunol; 1999 Aug; 29(8):2367-75. PubMed ID: 10458748
[TBL] [Abstract][Full Text] [Related]
6. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen.
Cardoso AA; Schultze JL; Boussiotis VA; Freeman GJ; Seamon MJ; Laszlo S; Billet A; Sallan SE; Gribben JG; Nadler LM
Blood; 1996 Jul; 88(1):41-8. PubMed ID: 8704200
[TBL] [Abstract][Full Text] [Related]
7. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma.
Stopeck AT; Gessner A; Miller TP; Hersh EM; Johnson CS; Cui H; Frutiger Y; Grogan TM
Clin Cancer Res; 2000 Oct; 6(10):3904-9. PubMed ID: 11051236
[TBL] [Abstract][Full Text] [Related]
8. CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model.
Van Gool SW; Vandenberghe P; de Boer M; Ceuppens JL
Immunol Rev; 1996 Oct; 153():47-83. PubMed ID: 9010719
[TBL] [Abstract][Full Text] [Related]
9. Costimulatory molecules in Wegener's granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells.
Moosig F; Csernok E; Wang G; Gross WL
Clin Exp Immunol; 1998 Oct; 114(1):113-8. PubMed ID: 9764612
[TBL] [Abstract][Full Text] [Related]
10. Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas.
Chaperot L; Plumas J; Jacob MC; Bost F; Molens JP; Sotto JJ; Bensa JC
Exp Hematol; 1999 Mar; 27(3):479-88. PubMed ID: 10089910
[TBL] [Abstract][Full Text] [Related]
11. CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity.
Vonderheide RH; Butler MO; Liu JF; Battle TE; Hirano N; Gribben JG; Frank DA; Schultze JL; Nadler LM
Int J Oncol; 2001 Oct; 19(4):791-8. PubMed ID: 11562757
[TBL] [Abstract][Full Text] [Related]
12. CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy?
van Gool SW; Barcy S; Devos S; Vandenberghe P; Ceuppens JL; Thielemans K; de Boer M
Res Immunol; 1995; 146(3):183-96. PubMed ID: 8525052
[No Abstract] [Full Text] [Related]
13. Induction of alloantigen-specific tolerance by B cells from CD40-deficient mice.
Holländer GA; Castigli E; Kulbacki R; Su M; Burakoff SJ; Gutierrez-Ramos JC; Geha RS
Proc Natl Acad Sci U S A; 1996 May; 93(10):4994-8. PubMed ID: 8643517
[TBL] [Abstract][Full Text] [Related]
14. Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma.
Suvas S; Singh V; Sahdev S; Vohra H; Agrewala JN
J Biol Chem; 2002 Mar; 277(10):7766-75. PubMed ID: 11726649
[TBL] [Abstract][Full Text] [Related]
15. Alloantigen-specific T-cell anergy induced by human keratinocytes is abrogated upon loss of cell-cell contact.
Otten HG; Bor B; Ververs C; Verdonck LF; De Boer M; De Gast GC
Immunology; 1996 Jun; 88(2):214-9. PubMed ID: 8690453
[TBL] [Abstract][Full Text] [Related]
16. Functional consequences of dysregulated B7-1 (CD80) and B7-2 (CD86) expression in B or T lymphocytes of transgenic mice.
Van Parijs L; Sethna MP; Schweitzer AN; Borriello F; Sharpe AH; Abbas AK
J Immunol; 1997 Dec; 159(11):5336-44. PubMed ID: 9548473
[TBL] [Abstract][Full Text] [Related]
17. Costimulatory molecules (CD80 and CD86) on Reed-Sternberg cells are associated with the proliferation of background T cells in Hodgkin's disease.
Nozawa Y; Wakasa H; Abe M
Pathol Int; 1998 Jan; 48(1):10-4. PubMed ID: 9589458
[TBL] [Abstract][Full Text] [Related]
18. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
[TBL] [Abstract][Full Text] [Related]
19. Induction of T cell anergy in the absence of CTLA-4/B7 interaction.
Frauwirth KA; Alegre ML; Thompson CB
J Immunol; 2000 Mar; 164(6):2987-93. PubMed ID: 10706686
[TBL] [Abstract][Full Text] [Related]
20. B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses.
Zhang YQ; Joost van Neerven RJ; Van Gool SW; Coorevits L; de Boer M; Ceuppens JL
Int Immunol; 1997 Aug; 9(8):1095-102. PubMed ID: 9263006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
